FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 350:1495-1504 April 8, 2004 Number 15 Next

	Full Text PDF PDA Full Text PowerPoint Slide Set Editorial by Topol, E. J. Letters Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear Related Article PubMed Citation

ABSTRACT

Background Lipid-lowering therapy with statins reduces the risk of cardiovascular events, but the optimal level of low-density lipoprotein (LDL) cholesterol is unclear.

Methods We enrolled 4162 patients who had been hospitalized for an acute coronary syndrome within the preceding 10 days and compared 40 mg of pravastatin daily (standard therapy) with 80 mg of atorvastatin daily (intensive therapy). The primary end point was a composite of death from any cause, myocardial infarction, documented unstable angina requiring rehospitalization, revascularization (performed at least 30 days after randomization), and stroke. The study was designed to establish the noninferiority of pravastatin as compared with atorvastatin with respect to the time to an end-point event. Follow-up lasted 18 to 36 months (mean, 24).

Results The median LDL cholesterol level achieved during treatment was 95 mg per deciliter (2.46 mmol per liter) in the standard-dose pravastatin group and 62 mg per deciliter (1.60 mmol per liter) in the high-dose atorvastatin group (P<0.001). Kaplan–Meier estimates of the rates of the primary end point at two years were 26.3 percent in the pravastatin group and 22.4 percent in the atorvastatin group, reflecting a 16 percent reduction in the hazard ratio in favor of atorvastatin (P=0.005; 95 percent confidence interval, 5 to 26 percent). The study did not meet the prespecified criterion for equivalence but did identify the superiority of the more intensive regimen.

Conclusions Among patients who have recently had an acute coronary syndrome, an intensive lipid-lowering statin regimen provides greater protection against death or major cardiovascular events than does a standard regimen. These findings indicate that such patients benefit from early and continued lowering of LDL cholesterol to levels substantially below current target levels.

Source Information

From the Thrombolysis in Myocardial Infarction (TIMI) Study Group, Cardiovascular Division, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston (C.P.C., E.B., C.H.M., M.A.P.); the University of Pennsylvania, Philadelphia (D.J.R.); the University of Montreal, Montreal (J.L.R.); Bristol-Myers Squibb, Princeton, N.J. (R.B., S.V.J.); and the Nottingham Clinical Research Group, Nottingham, United Kingdom (K.A.H., A.M.S.).

This article was published at www.nejm.org on March 8, 2004.

Address reprint requests to Dr. Cannon at the TIMI Study Group, Cardiovascular Division, Brigham and Women's Hospital, 75 Francis St., Boston, MA 02115, or at cpcannon{at}partners.org.

Full Text of this Article

Related Letters:

Intensive versus Moderate Lipid Lowering with Statins after Acute Coronary Syndromes
van der Harst P., Voors A. A., van Veldhuisen D. J., Miller M., Gotto A. M. Jr., Paradis J.-M., LeLorier J., Auer J., Weber T., Eber B., Cannon C. P., Braunwald E.
Extract | Full Text | PDF  
N Engl J Med 2004; 351:714-717, Aug 12, 2004. Correspondence

This article has been cited by other articles:

• Heusch, G., Kleinbongard, P., Bose, D., Levkau, B., Haude, M., Schulz, R., Erbel, R. (2009). Coronary Microembolization: From Bedside to Bench and Back to Bedside. Circulation 120: 1822-1836 [Abstract] [Full Text]  
• Kamari, Y., Bitzur, R., Cohen, H., Shaish, A., Harats, D. (2009). Should All Diabetic Patients Be Treated With a Statin?. Diabetes Care 32: S378-S383 [Full Text]  
• Eldor, R., Raz, I. (2009). American Diabetes Association Indications for Statins in Diabetes: Is there evidence?. Diabetes Care 32: S384-S391 [Full Text]  
• Voora, D., Shah, S. H., Spasojevic, I., Ali, S., Reed, C. R., Salisbury, B. A., Ginsburg, G. S. (2009). The SLCO1B1*5 genetic variant is associated with statin-induced side effects.. J Am Coll Cardiol 54: 1609-1616 [Abstract] [Full Text]  
• Corp, E.V., Antoniou, S., Wright, P.G., Khachi, H., Vercaeren, S., Wald, D.S. (2009). Use and cost of branded and generic drugs in patients with coronary heart disease--results from a prospective survey of 1008 patients in two London hospitals. QJM 0: hcp127v1-hcp127 [Abstract] [Full Text]  
• Chapman, M. J., Le Goff, W., Guerin, M., Kontush, A. (2009). Cholesteryl ester transfer protein: at the heart of the action of lipid-modulating therapy with statins, fibrates, niacin, and cholesteryl ester transfer protein inhibitors. Eur Heart J 0: ehp399v1-ehp399 [Abstract] [Full Text]  
• Morrissey, R. P., Diamond, G. A., Kaul, S. (2009). Statins in Acute Coronary Syndromes: Do the Guideline Recommendations Match the Evidence?. J Am Coll Cardiol 54: 1425-1433 [Abstract] [Full Text]  
• Waters, D. D., Ku, I. (2009). Early Statin Therapy in Acute Coronary Syndromes: The Successful Cycle of Evidence, Guidelines, and Implementation. J Am Coll Cardiol 54: 1434-1437 [Abstract] [Full Text]  
• Pride, Y. B., Canto, J. G., Frederick, P. D., Gibson, C. M., for the NRMI Investigators, (2009). Outcomes Among Patients With Non-ST-Segment Elevation Myocardial Infarction Presenting to Interventional Hospitals With and Without On-Site Cardiac Surgery. J Am Coll Cardiol Intv 2: 944-952 [Abstract] [Full Text]  
• Kumar, A., Cannon, C. P. (2009). Acute Coronary Syndromes: Diagnosis and Management, Part I. Mayo Clin Proc. 84: 917-938 [Abstract] [Full Text]  
• American College of Cardiology Foundation, , American Heart Association, , American College of Physicians Task Force on Compe, , American Academy of Neurology, , American Association of Cardiovascular and Pulmona, , American College of Preventive Medicine, , American Diabetes Association, , American Society of Hypertension, , Association of Black Cardiologists, , National Lipid Association, , Preventive Cardiovascular Nurses Association, , Bairey Merz, C. N., Alberts, M. J., Balady, G. J., Ballantyne, C. M., Berra, K., Black, H. R., Blumenthal, R. S., Davidson, M. H., Fazio, S. B., Ferdinand, K. C., Fine, L. J., Fonseca, V., Franklin, B. A., McBride, P. E., Mensah, G. A., Merli, G. J., O'Gara, P. T., Thompson, P. D., Underberg, J. A. (2009). ACCF/AHA/ACP 2009 competence and training statement: a curriculum on prevention of cardiovascular disease.. J Am Coll Cardiol 54: 1336-1363 [Full Text]  
• WRITING COMMITTEE MEMBERS, , Bairey Merz, C. N., Alberts, M. J., Balady, G. J., Ballantyne, C. M., Berra, K., Black, H. R., Blumenthal, R. S., Davidson, M. H., Fazio, S. B., Ferdinand, K. C., Fine, L. J., Fonseca, V., Franklin, B. A., McBride, P. E., Mensah, G. A., Merli, G. J., O'Gara, P. T., Thompson, P. D., Underberg, J. A. (2009). ACCF/AHA/ACP 2009 Competence and Training Statement: A Curriculum on Prevention of Cardiovascular Disease: A Report of the American College of Cardiology Foundation/American Heart Association/American College of Physicians Task Force on Competence and Training (Writing Committee to Develop a Competence and Training Statement on Prevention of Cardiovascular Disease): Developed in Collaboration With the American Academy of Neurology; American Association of Cardiovascular and Pulmonary Rehabilitation; American College of Preventive Medicine; American College of Sports Medicine; American Diabetes Association; American Society of Hypertension; Association of Black Cardiologists; Centers for Disease Control and Prevention; National Heart, Lung, and Blood Institute; National Lipid Association; and Preventive Cardiovascular Nurses Association. Circulation 120: e100-e126 [Full Text]  
• Mascitelli, L., Pezzetta, F., Goldstein, M. R (2009). Letter to the Editor. AMERICAN JOURNAL OF LIFESTYLE MEDICINE 3: 410-411  
• Liakopoulos, O. J., Choi, Y.-H., Kuhn, E. W., Wittwer, T., Borys, M., Madershahian, N., Wassmer, G., Wahlers, T. (2009). Statins for prevention of atrial fibrillation after cardiac surgery: a systematic literature review.. J. Thorac. Cardiovasc. Surg. 138: 678-686.e1 [Abstract] [Full Text]  
• Miller, M. (2009). Dyslipidemia and cardiovascular risk: the importance of early prevention. QJM 102: 657-667 [Abstract] [Full Text]  
• Mega, J. L., Morrow, D. A., Brown, A., Cannon, C. P., Sabatine, M. S. (2009). Identification of Genetic Variants Associated With Response to Statin Therapy. Arterioscler. Thromb. Vasc. Bio. 29: 1310-1315 [Abstract] [Full Text]  
• Zuo, Y., Yancey, P., Castro, I., Khan, W., Motojima, M., Ichikawa, I., Fogo, A. B., Linton, M. F., Fazio, S., Kon, V. (2009). Renal Dysfunction Potentiates Foam Cell Formation by Repressing ABCA1. Arterioscler. Thromb. Vasc. Bio. 29: 1277-1282 [Abstract] [Full Text]  
• Liu, P.-Y., Liao, J. K., Liu, Y.-W., Lin, L.-J., Chen, J.-H. (2009). Response to Letters Regarding Article, "Evidence for Statin Pleiotropy in Humans: Differential Effects of Statins and Ezetimibe on Rho-Associated Coiled-Coil Containing Protein Kinase Activity, Endothelial Function, and Inflammation". Circulation 120: e69-e70 [Full Text]  
• Berger, J. S., Petersen, J. L., Brown, D. L. (2009). Vascular Disease Burden and In-Hospital Outcomes Among Patients Undergoing Percutaneous Coronary Intervention in New York State. Circ Cardiovasc Interv 2: 317-322 [Abstract] [Full Text]  
• Hiro, T., Kimura, T., Morimoto, T., Miyauchi, K., Nakagawa, Y., Yamagishi, M., Ozaki, Y., Kimura, K., Saito, S., Yamaguchi, T., Daida, H., Matsuzaki, M., for the JAPAN-ACS Investigators, (2009). Effect of intensive statin therapy on regression of coronary atherosclerosis in patients with acute coronary syndrome: a multicenter randomized trial evaluated by volumetric intravascular ultrasound using pitavastatin versus atorvastatin (JAPAN-ACS [Japan assessment of pitavastatin and atorvastatin in acute coronary syndrome] study).. J Am Coll Cardiol 54: 293-302 [Abstract] [Full Text]  
• Braunwald, E. (2009). Adventures in Cardiovascular Research. Circulation 120: 170-180 [Abstract] [Full Text]  
• Jackevicius, C. A., Cox, J. L., Carreon, D., Tu, J. V., Rinfret, S., So, D., Johansen, H., Kalavrouziotis, D., Demers, V., Humphries, K., Pilote, L., for the Canadian Cardiovascular Outcomes Research, (2009). Long-term trends in use of and expenditures for cardiovascular medications in Canada. CMAJ 181: E19-E28 [Abstract] [Full Text]  
• Schiele, F., Meneveau, N., Seronde, M. F., Chopard, R., Descotes-Genon, V., Dutheil, J., Bassand, J.-P., on behalf on the 'Reseau de Cardiologie de Franche, (2009). C-reactive protein improves risk prediction in patients with acute coronary syndromes. Eur Heart J 0: ehp273v1-ehp273 [Abstract] [Full Text]  
• Hong, M.-K., Park, D.-W., Lee, C.-W., Lee, S.-W., Kim, Y.-H., Kang, D.-H., Song, J.-K., Kim, J.-J., Park, S.-W., Park, S.-J. (2009). Effects of Statin Treatments on Coronary Plaques Assessed by Volumetric Virtual Histology Intravascular Ultrasound Analysis. J Am Coll Cardiol Intv 2: 679-688 [Abstract] [Full Text]  
• Samady, H., McDaniel, M. C. (2009). Can Statins Alter Coronary Plaque Composition Assessed by Radiofrequency Backscatter Intravascular Ultrasound?. J Am Coll Cardiol Intv 2: 697-700 [Full Text]  
• Tsai, M. Y., Ordovas, J. M. (2009). APOC3 Mutation, Serum Triglyceride Concentrations, and Coronary Heart Disease. Clin. Chem. 55: 1274-1276 [Full Text]  
• Goumas, G. S. (2009). LDL-Cholesterol is the King. ANGIOLOGY 60: 387-388  
• Leone, A. M., Valgimigli, M., Giannico, M. B., Zaccone, V., Perfetti, M., D'Amario, D., Rebuzzi, A. G., Crea, F. (2009). From bone marrow to the arterial wall: the ongoing tale of endothelial progenitor cells. Eur Heart J 30: 890-899 [Abstract] [Full Text]  
• Schlitt, A., Blankenberg, S., Bickel, C., Lackner, K. J., Heine, G. H., Buerke, M., Werdan, K., Maegdefessel, L., Raaz, U., Rupprecht, H. J., Munzel, T., Jiang, X.-C. (2009). PLTP activity is a risk factor for subsequent cardiovascular events in CAD patients under statin therapy: the AtheroGene Study. J. Lipid Res. 50: 723-729 [Abstract] [Full Text]  
• Stein, E. A. (2009). Low-Density Lipoprotein Cholesterol Reduction and Prevention of Cardiovascular Disease. Mayo Clin Proc. 84: 307-309 [Full Text]  
• Karalis, D. G. (2009). Intensive Lowering of Low-Density Lipoprotein Cholesterol Levels for Primary Prevention of Coronary Artery Disease. Mayo Clin Proc. 84: 345-352 [Abstract] [Full Text]  
• Chhatriwalla, A. K., Nicholls, S. J., Wang, T. H., Wolski, K., Sipahi, I., Crowe, T., Schoenhagen, P., Kapadia, S., Tuzcu, E. M., Nissen, S. E. (2009). Low levels of low-density lipoprotein cholesterol and blood pressure and progression of coronary atherosclerosis.. J Am Coll Cardiol 53: 1110-1115 [Abstract] [Full Text]  
• Ray, K. K., Cannon, C. P., Cairns, R., Morrow, D. A., Ridker, P. M, Braunwald, E. (2009). Prognostic Utility of ApoB/AI, Total Cholesterol/HDL, Non-HDL Cholesterol, or hs-CRP as Predictors of Clinical Risk in Patients Receiving Statin Therapy After Acute Coronary Syndromes: Results From PROVE IT-TIMI 22. Arterioscler. Thromb. Vasc. Bio. 29: 424-430 [Abstract] [Full Text]  
• Lester, S. J., Eleid, M. F., Khandheria, B. K., Hurst, R. T. (2009). Carotid Intima-Media Thickness and Coronary Artery Calcium Score as Indications of Subclinical Atherosclerosis. Mayo Clin Proc. 84: 229-233 [Abstract] [Full Text]  
• Fitzgerald, T. N, Popp, C., Dardik, A., Federman, D. G (2009). Lipid goal achievement and trends in lipid-lowering therapy in veterans undergoing carotid endarterectomy. Vasc Med 14: 21-27 [Abstract]  
• Scirica, B. M., Cannon, C. P., Sabatine, M. S., Jarolim, P., Sloane, S., Rifai, N., Braunwald, E., Morrow, D. A., for the PROVE IT-TIMI 22 Investigators, (2009). Concentrations of C-Reactive Protein and B-Type Natriuretic Peptide 30 Days after Acute Coronary Syndromes Independently Predict Hospitalization for Heart Failure and Cardiovascular Death. Clin. Chem. 55: 265-273 [Abstract] [Full Text]  
• Robinson, J. G., Wang, S., Smith, B. J., Jacobson, T. A. (2009). Meta-analysis of the relationship between non-high-density lipoprotein cholesterol reduction and coronary heart disease risk.. J Am Coll Cardiol 53: 316-322 [Abstract] [Full Text]  
• Ganz, P., Hsue, P. Y. (2009). Individualized approach to the management of coronary heart disease identifying the nonresponders before it is too late.. J Am Coll Cardiol 53: 331-333 [Full Text]  
• Choudhry, N. K. (2009). Copayment Levels and Medication Adherence: Less Is More. Circulation 119: 365-367 [Full Text]  
• Liu, P.-Y., Liu, Y.-W., Lin, L.-J., Chen, J.-H., Liao, J. K. (2009). Evidence for Statin Pleiotropy in Humans: Differential Effects of Statins and Ezetimibe on Rho-Associated Coiled-Coil Containing Protein Kinase Activity, Endothelial Function, and Inflammation. Circulation 119: 131-138 [Abstract] [Full Text]  
• SHISHEHBOR, M. H., HAZEN, S. L. (2009). JUPITER to Earth: A statin helps people with normal LDL-C and high hs-CRP, but what does it mean?. Cleveland Clinic Journal of Medicine 76: 37-44 [Abstract] [Full Text]  
• Hollenberg, S. M. (2009). Acute Coronary Syndromes. ACCP Crit Care Med Brd Rev 20: 129-144 [Full Text]  
• Whayne, T. F. Jr (2009). Is There a Problem With Ezetimibe or Just ENHANCEd Hype?. ANGIOLOGY 59: 661-663  
• Spatz, E. S., Canavan, M. E., Desai, M. M. (2009). From Here to JUPITER: Identifying New Patients for Statin Therapy Using Data From the 1999-2004 National Health and Nutrition Examination Survey. Circ Cardiovasc Qual Outcomes 2: 41-48 [Abstract] [Full Text]  
• McConnell, J. P., Jaffe, A. S. (2009). The Spin Stops Here: Inhibition of Lipoprotein-Associated Phospholipase A2-- A Promising Target but a Negative Initial Trial?. Clin. Chem. 55: 21-23 [Full Text]  
• American Diabetes Association, (2009). Standards of Medical Care in Diabetes--2009. Diabetes Care 32: S13-S61 [Full Text]  
• Cosentino, F., Rydén, L., Francia, P., Mellbin, L. G. (2009). CHAPTER 14 Diabetes Mellitus and Metabolic Syndrome. ESC Textbook of Cardiovascular Medicine 2: med-9780199566990-chapter-med-9780199566990-chapter [Abstract] [Full Text]  
• Caron, S., Staels, B. (2008). Apolipoprotein CIII: A Link Between Hypertriglyceridemia and Vascular Dysfunction?. Circ. Res. 103: 1348-1350 [Full Text]  
• Mukherjee, R., Locke, K. T., Miao, B., Meyers, D., Monshizadegan, H., Zhang, R., Search, D., Grimm, D., Flynn, M., O'Malley, K. M., Zhang, L., Li, J., Shi, Y., Kennedy, L. J., Blanar, M., Cheng, P. T., Tino, J., Srivastava, R. A. (2008). Novel Peroxisome Proliferator-Activated Receptor {alpha} Agonists Lower Low-Density Lipoprotein and Triglycerides, Raise High-Density Lipoprotein, and Synergistically Increase Cholesterol Excretion with a Liver X Receptor Agonist. J. Pharmacol. Exp. Ther. 327: 716-726 [Abstract] [Full Text]  
• Jukema, J W., Bergheanu, S. C (2008). Statins: established indications and controversial subgroups. Heart 94: 1656-1662 [Full Text]  
• Krasuski, R. A. (2008). Primary Prevention and Statins: Is It Just About Going to Class?. Mayo Clin Proc. 83: 1313-1315 [Full Text]  
• Jacobson, T. A., Wertz, D. A., Hoy, T., Kuznik, A., Grochulski, D., Cziraky, M. (2008). Comparison of Cardiovascular Event Rates in Patients Without Cardiovascular Disease in Whom Atorvastatin or Simvastatin Was Newly Initiated. Mayo Clin Proc. 83: 1316-1325 [Abstract] [Full Text]  
• Mills, E. J., Rachlis, B., Wu, P., Devereaux, P. J., Arora, P., Perri, D. (2008). Primary Prevention of Cardiovascular Mortality and Events With Statin Treatments A Network Meta-Analysis Involving More Than 65,000 Patients.. J Am Coll Cardiol 52: 1769-1781 [Abstract] [Full Text]  
• Fruchart, J.-C., Sacks, F. M, Hermans, M. P, Assmann, G., Brown, W V., Ceska, R., Chapman, M J., Dodson, P. M, Fioretto, P., Ginsberg, H. N, Kadowaki, T., Lablanche, J.-M., Marx, N., Plutzky, J., Reiner, Z., Rosenson, R. S, Staels, B., Stock, J. K, Sy, R., Wanner, C., Zambon, A., Zimmet, P. (2008). The Residual Risk Reduction Initiative: a call to action to reduce residual vascular risk in dyslipidaemic patients. Diabetes and Vascular Disease Research 5: 319-335 [Abstract]  
• van der Hoorn, J. W.A., de Haan, W., Berbee, J. F.P., Havekes, L. M., Jukema, J. W., Rensen, P. C.N., Princen, H. M.G. (2008). Niacin Increases HDL by Reducing Hepatic Expression and Plasma Levels of Cholesteryl Ester Transfer Protein in APOE*3Leiden.CETP Mice. Arterioscler. Thromb. Vasc. Bio. 28: 2016-2022 [Abstract] [Full Text]  
• O'Keefe, J. H., Bybee, K. A., Lavie, C. J. (2008). Is Carotid Intima-Media Thickness a Reliable Clinical Predictor?-Reply-I. Mayo Clin Proc. 83: 1300-1301 [Full Text]  
• Roe, M. T., Ou, F.-S., Alexander, K. P., Newby, L. K., Foody, J. M., Gibler, W. B., Boden, W. E., Ohman, E. M., Smith, S. C. Jr, Peterson, E. D. (2008). Patterns and prognostic implications of low high-density lipoprotein levels in patients with non-ST-segment elevation acute coronary syndromes. Eur Heart J 29: 2480-2488 [Abstract] [Full Text]  
• Johnson, E. L., Brosseau, J. D., Soule, M., Kolberg, J. (2008). Treatment of Diabetes in Long-Term Care Facilities: A Primary Care Approach. Clin. Diabetes 26: 152-156 [Abstract] [Full Text]  
• Rosenzweig, J. L., Ferrannini, E., Grundy, S. M., Haffner, S. M., Heine, R. J., Horton, E. S., Kawamori, R. (2008). Primary Prevention of Cardiovascular Disease and Type 2 Diabetes in Patients at Metabolic Risk: An Endocrine Society Clinical Practice Guideline. J. Clin. Endocrinol. Metab. 93: 3671-3689 [Abstract] [Full Text]  
• Giraldez, R. R., Giugliano, R. P., Mohanavelu, S., Murphy, S. A., McCabe, C. H., Cannon, C. P., Braunwald, E. (2008). Baseline Low-Density Lipoprotein Cholesterol Is an Important Predictor of the Benefit of Intensive Lipid-Lowering Therapy: A PROVE IT-TIMI 22 (Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis In Myocardial Infarction 22) Analysis. J Am Coll Cardiol 52: 914-920 [Abstract] [Full Text]  
• Bruschke, A. V.G., Jukema, J. W. (2008). Aggressive Therapy Is Not Always the Best Therapy. J Am Coll Cardiol 52: 921-923 [Full Text]  
• Serruys, P. W., Garcia-Garcia, H. M., Buszman, P., Erne, P., Verheye, S., Aschermann, M., Duckers, H., Bleie, O., Dudek, D., Botker, H. E., von Birgelen, C., D'Amico, D., Hutchinson, T., Zambanini, A., Mastik, F., van Es, G.-A., van der Steen, A. F.W., Vince, D. G., Ganz, P., Hamm, C. W., Wijns, W., Zalewski, A., for the Integrated Biomarker and Imaging Study-2 I, (2008). Effects of the Direct Lipoprotein-Associated Phospholipase A2 Inhibitor Darapladib on Human Coronary Atherosclerotic Plaque. Circulation 118: 1172-1182 [Abstract] [Full Text]  
• FELDMAN, L. S., BROTMAN, D. J. (2008). Perioperative statins: More than lipid-lowering?. Cleveland Clinic Journal of Medicine 75: 654-662 [Abstract] [Full Text]  
• Newman, C. B, Szarek, M., Colhoun, H. M, Betteridge, D J., Durrington, P. N, Hitman, G. A, Neil, H A. W, Demicco, D. A, Auster, S., Fuller, J. H (2008). The safety and tolerability of atorvastatin 10 mg in the Collaborative Atorvastatin Diabetes Study (CARDS). Diabetes and Vascular Disease Research 5: 177-183 [Abstract]  
• Gill, J. M., Yingxia Chen, (2008). Quality of Lipid Management in Outpatient Care: A National Study Using Electronic Health Records. American Journal of Medical Quality 23: 375-381 [Abstract]  
• The SEARCH Collaborative Group, (2008). SLCO1B1 Variants and Statin-Induced Myopathy -- A Genomewide Study. NEJM 359: 789-799 [Abstract] [Full Text]  
• Zoghbi, G. J., Dorfman, T. A., Iskandrian, A. E. (2008). The Effects of Medications on Myocardial Perfusion. J Am Coll Cardiol 52: 401-416 [Abstract] [Full Text]  
• Steinberg, D., Glass, C. K., Witztum, J. L. (2008). Evidence Mandating Earlier and More Aggressive Treatment of Hypercholesterolemia. Circulation 118: 672-677 [Full Text]  
• Chan, M. Y., Mahaffey, K. W., Sun, L. J., Pieper, K. S., White, H. D., Aylward, P. E., Ferguson, J. J., Califf, R. M., Roe, M. T. (2008). Prevalence, Predictors, and Impact of Conservative Medical Management for Patients With Non-ST-Segment Elevation Acute Coronary Syndromes Who Have Angiographically Documented Significant Coronary Disease. J Am Coll Cardiol Intv 1: 369-378 [Abstract] [Full Text]  
• Woodard, J., Sassano, A., Hay, N., Platanias, L. C. (2008). Statin-Dependent Suppression of the Akt/Mammalian Target of Rapamycin Signaling Cascade and Programmed Cell Death 4 Up-Regulation in Renal Cell Carcinoma. Clin. Cancer Res. 14: 4640-4649 [Abstract] [Full Text]  
• Settergren, M., Bohm, F., Ryden, L., Pernow, J. (2008). Cholesterol lowering is more important than pleiotropic effects of statins for endothelial function in patients with dysglycaemia and coronary artery disease. Eur Heart J 29: 1753-1760 [Abstract] [Full Text]  
• DAVIDSON, M. H. (2008). Is ezetimibe/simvastatin no better than simvastatin alone? Lessons learned and clinical implications. Cleveland Clinic Journal of Medicine 75: 479-496 [Full Text]  
• White, J. R. Jr (2008). Do People With Diabetes Need Statins?. The Diabetes Educator 34: 664-673 [Abstract] [Full Text]  
• Geisler, T., Zurn, C., Paterok, M., Gohring-Frischholz, K., Bigalke, B., Stellos, K., Seizer, P., Kraemer, B. F., Dippon, J., May, A. E., Herdeg, C., Gawaz, M. (2008). Statins do not adversely affect post-interventional residual platelet aggregation and outcomes in patients undergoing coronary stenting treated by dual antiplatelet therapy. Eur Heart J 29: 1635-1643 [Abstract] [Full Text]  
• Pedersen, T. R. (2008). Overview of clinical trials on calcific aortic stenosis. Eur Heart J Suppl 10: E31-E40 [Abstract] [Full Text]  
• Shah, S. J., Waters, D. D., Barter, P., Kastelein, J. J.P., Shepherd, J., Wenger, N. K., DeMicco, D. A., Breazna, A., LaRosa, J. C. (2008). Intensive Lipid-Lowering With Atorvastatin for Secondary Prevention in Patients After Coronary Artery Bypass Surgery. J Am Coll Cardiol 51: 1938-1943 [Abstract] [Full Text]  
• Bunch, T. J., Rihal, C. S., Gumina, R. J., Cooper, L., Caplice, N. M. (2008). Progression of Nonculprit Plaque Stenosis Following Successful Percutaneous Intervention. ANGIOLOGY 59: 236-239 [Abstract]  
• Mohler, E. R. III, Ballantyne, C. M., Davidson, M. H., Hanefeld, M., Ruilope, L. M., Johnson, J. L., Zalewski, A., for the Darapladib Investigators, (2008). The Effect of Darapladib on Plasma Lipoprotein-Associated Phospholipase A2 Activity and Cardiovascular Biomarkers in Patients With Stable Coronary Heart Disease or Coronary Heart Disease Risk Equivalent: The Results of a Multicenter, Randomized, Double-Blind, Placebo-Controlled Study. J Am Coll Cardiol 51: 1632-1641 [Abstract] [Full Text]  
• Ky, B., Burke, A., Tsimikas, S., Wolfe, M. L., Tadesse, M. G., Szapary, P. O., Witztum, J. L., FitzGerald, G. A., Rader, D. J. (2008). The Influence of Pravastatin and Atorvastatin on Markers of Oxidative Stress in Hypercholesterolemic Humans. J Am Coll Cardiol 51: 1653-1662 [Abstract] [Full Text]  
• Ambrose, J. A. (2008). In Search of the "vulnerable plaque": can it be localized and will focal regional therapy ever be an option for cardiac prevention?. J Am Coll Cardiol 51: 1539-1542 [Abstract] [Full Text]  
• Pitt, B., Loscalzo, J., Ycas, J., Raichlen, J. S. (2008). Lipid Levels After Acute Coronary Syndromes. J Am Coll Cardiol 51: 1440-1445 [Abstract] [Full Text]  
• Miller, M. (2008). Lipid Levels in the Post-Acute Coronary Syndrome Setting: Destabilizing Another Myth?. J Am Coll Cardiol 51: 1446-1447 [Full Text]  
• Howard, B. V., Roman, M. J., Devereux, R. B., Fleg, J. L., Galloway, J. M., Henderson, J. A., Howard, Wm. J., Lee, E. T., Mete, M., Poolaw, B., Ratner, R. E., Russell, M., Silverman, A., Stylianou, M., Umans, J. G., Wang, W., Weir, M. R., Weissman, N. J., Wilson, C., Yeh, F., Zhu, J. (2008). Effect of Lower Targets for Blood Pressure and LDL Cholesterol on Atherosclerosis in Diabetes: The SANDS Randomized Trial. JAMA 299: 1678-1689 [Abstract] [Full Text]  
• Kastelein, J. J.P., Akdim, F., Stroes, E. S.G., Zwinderman, A. H., Bots, M. L., Stalenhoef, A. F.H., Visseren, F. L.J., Sijbrands, E. J.G., Trip, M. D., Stein, E. A., Gaudet, D., Duivenvoorden, R., Veltri, E. P., Marais, A. D., de Groot, E., the ENHANCE Investigators, (2008). Simvastatin with or without Ezetimibe in Familial Hypercholesterolemia. NEJM 358: 1431-1443 [Abstract] [Full Text]  
• Kastelein, J. J.P., de Groot, E. (2008). Ultrasound imaging techniques for the evaluation of cardiovascular therapies. Eur Heart J 29: 849-858 [Abstract] [Full Text]  
• Ibanez, B., Vilahur, G., Cimmino, G., Speidl, W. S., Pinero, A., Choi, B. G., Zafar, M. U., Santos-Gallego, C. G., Krause, B., Badimon, L., Fuster, V., Badimon, J. J. (2008). Rapid change in plaque size, composition, and molecular footprint after recombinant apolipoprotein A-I Milano (ETC-216) administration: magnetic resonance imaging study in an experimental model of atherosclerosis.. J Am Coll Cardiol 51: 1104-1109 [Abstract] [Full Text]  
• Lewis, E. F., Velazquez, E. J., Solomon, S. D., Hellkamp, A. S., McMurray, J. J.V., Mathias, J., Rouleau, J.-L., Maggioni, A. P., Swedberg, K., Kober, L., White, H., Dalby, A. J., Francis, G. S., Zannad, F., Califf, R. M., Pfeffer, M. A. (2008). Predictors of the first heart failure hospitalization in patients who are stable survivors of myocardial infarction complicated by pulmonary congestion and/or left ventricular dysfunction: a VALIANT study. Eur Heart J 29: 748-756 [Abstract] [Full Text]  
• Birnbaum, Y., Lin, Y., Ye, Y., Merla, R., Perez-Polo, J. R., Uretsky, B. F. (2008). Pretreatment With High-Dose Statin, But Not Low-Dose Statin, Ezetimibe, or the Combination of Low-Dose Statin and Ezetimibe, Limits Infarct Size in the Rat. J CARDIOVASC PHARMACOL THER 13: 72-79 [Abstract]  
• Josan, K. MD, Majumdar, S. R. MD MPH, McAlister, F. A. MD MSc (2008). The efficacy and safety of intensive statin therapy: a meta-analysis of randomized trials. CMAJ 178: 576-584 [Abstract] [Full Text]